Danish translation and cultural adaptation of the Psoriatic arthritis UnclutteRed screening Evaluation (PURE-4) scale

Abstract

Objectives

Screening tools are needed to help to identify psoriatic arthritis in patients with psoriasis. The Psoriatic arthritis UnclutteRed screening Evaluation (PURE-4) questionnaire was developed for this purpose and has been shown to perform very well. The aim of this study was to translate and culturally adapt the PURE-4 scale into the Danish language.

Method

The translational process followed the guidelines provided by the Mapi Research Trust, which include the following steps: forward translation, backward translation, cognitive interviews, and proofreading. Following the guidelines helps to maintain the content validity of the questionnaire and secures a translation that is both literally and culturally appropriate for the target population.

Results

All four items were modified throughout the translation process, involving mainly minor changes such as the addition of more colloquial words in the Danish version. The new Danish version of PURE-4 was reviewed and approved by the original developers.

Conclusions

A Danish version of the PURE-4 questionnaire was produced. The translation and cultural adaptation of PURE-4 constitute the first step in the validation of the questionnaire in Danish patients with psoriasis.

Disclosure statement

Cathrine Elgaard has received a personal scholarship from the Novo Nordisk Foundation outside the submitted work. Trine Laurberg reports no conflicts of interest. René Østgård has received fees for speaking and consultancy from Pfizer, Merck Sharp & Dohme, AbbVie, Bristol-Meyer-Squibb, Janssen, Novartis, and Lilly, and funding support from AbbVie and Novartis. Morten Pilegaard, Peter Steffensen, Marian Flanagan, and Antoinette Fage-Butler have received payment from the Department of Dermatology, Aarhus University Hospital, Denmark, for conducting the translation of the questionnaire. Anne Gitte Loft has received support from Pfizer for attending a congress. Kasper Hjuler has served as a consultant and advisor for the following companies: AbbVie, Bristol Myers Squibb (BMS), Janssen, LEO Pharma, UCB, and Novartis, and has received speaking fees or grants from AbbVie, Eli Lilly, LEO Pharma, Novartis, and Janssen.